Baroness Finlay of Llandaff

To ask His Majesty's Government whether they have considered changes to the use of individual funding requests for rare cancer treatments, particularly the requirement for exceptionality, for patients who have no alternative clinically appropriate treatme

To ask His Majesty's Government what assessment they have made of the impact of delays in commissioning decisions on (1) outcomes, and (2) quality of life, for patients with rare cancers.

To ask His Majesty's Government what consideration they have given to introducing time-limited interim access pathways for rare cancer treatments where published clinical evidence and specialist expertise already exist but routine commissioning routes are

To ask His Majesty's Government what interim arrangements are in place to ensure timely access to clinically appropriate treatments for patients with rare cancers, including metastatic ocular melanoma, while longer term commissioning decisions are under c

To ask His Majesty's Government what steps they are taking to ensure that patients with rare cancers are not without access to potentially life extending treatments while national appraisal and commissioning processes are ongoing.